

# Capsid protein inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/CD438CCA8895EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: CD438CCA8895EN

## Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Capsid protein inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 9+ companies and 9+ pipeline drugs in Capsid protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Capsid protein inhibitors Understanding

#### Capsid protein inhibitors: Overview

A capsid is the protein shell of a virus, enclosing its genetic material. It consists of several oligomeric structural subunits made of protein called protomers. The capsid has three functions: 1) it protects the nucleic acid from digestion by enzymes, 2) contains special sites on its surface that allow the virion to attach to a host cell, and 3) provides proteins that enable the virion to penetrate the host cell membrane. Capsid-targeting drugs are predicted to exhibit high barriers to viral resistance, and ongoing work in this area is contributing to an understanding of the molecular biology of HIV uncoating and maturation.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Capsid protein inhibitors R&D. The therapies under development are focused on novel approaches for Capsid protein inhibitors.

## Capsid protein inhibitors Emerging Drugs Chapters

This segment of the Capsid protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Capsid protein inhibitors Emerging Drugs

### Lenacapavir: Gilead Sciences

Lenacapavir is a potential first-in-class, long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV-1 infection. Lenacapavir's multi-stage mechanism of action is distinguishable from currently approved classes of antiviral agents and is designed to provide a new avenue for the development of long-acting therapy options for people living with or at risk for HIV-1. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV-1 at multiple stages of its lifecycle and has no known cross resistance to other existing drug classes.

### RG7907: Roche

CpAM (RG7907) is an orally administered small molecule, class I hepatitis B virus (HBV) core protein allosteric modulator, that disrupts HBV nucleocapsids assembly and induces the depletion of functional core proteins, thereby effectively inhibiting HBV replication. A phase I clinical trial is evaluating RG7907 for the treatment of chronic hepatitis B infection.

Further product details are provided in the report.....

## Capsid protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Capsid protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Capsid protein inhibitors

There are approx. 9+ key companies which are developing the Capsid protein inhibitors. The companies which have their Capsid protein inhibitors drug candidates in the most advanced stage, i.e. Preregistration include, Gilead Sciences.

Phases

DelveInsight's report covers around 9+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Capsid protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Capsid protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Capsid protein inhibitors therapeutic

drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Capsid protein inhibitors drugs.

### Capsid protein inhibitors Report Insights

Capsid protein inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

### Capsid protein inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

### Key Questions

#### Current Scenario and Emerging Therapies:

How many companies are developing Capsid protein inhibitors drugs?

How many Capsid protein inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Capsid protein inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Capsid protein inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Capsid protein inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Gilead Sciences

Roche

Janssen Sciences Ireland

GlaxoSmithKline

ViiV Healthcare

Protheragen

Arbutus Biopharma

Aviragen Therapeutics

Aligos Therapeutics

Alios BioPharma

## Key Products

Lenacapavir

RG 7907

Bersacapavir

GSK 3640254

Combinectin

GS CA1

ARB-168786

AB 836

BTA-798

ALG 000184

JNJ 440

## Contents

- Introduction
- Executive Summary
- Capsid protein inhibitors: Overview
  - Structure
  - Mechanism of Action
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Capsid protein inhibitors – DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
  - Comparative Analysis
- Lenacapavir: Gilead Sciences
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
  - Comparative Analysis
- Bersacapavir: Janssen Research & Development
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I and I/II)
  - Comparative Analysis
- RG7907: Roche
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products



Comparative Analysis  
GS CA1: Gilead Sciences  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report.....  
Inactive Products  
Comparative Analysis  
Capsid protein inhibitors Key Companies  
Capsid protein inhibitors Key Products  
Capsid protein inhibitors- Unmet Needs  
Capsid protein inhibitors- Market Drivers and Barriers  
Capsid protein inhibitors- Future Perspectives and Conclusion  
Capsid protein inhibitors Analyst Views  
Capsid protein inhibitors Key Companies  
Appendix

## I would like to order

Product name: Capsid protein inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/CD438CCA8895EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CD438CCA8895EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970